NeurologyLive® Friday 5 — April 17, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: Sustained Pain Relief Without Implant: Exploring Durability of Spinal Cord Stimulation Trials

In a recent Q&A, Alexander Shustorovich, DO, interventional pain medicine physician at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed a unique case of sustained pain relief after spinal cord stimulation trial presented at the 2026 Association of Academic Physiatrists (AAP) National Meeting.

2: Neurology by the Numbers

In honor of National Public Health Week, held April 6 to 12, 2026, a data-driven slideshow highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

3: MOGAD Awareness Month: From Emerging Entity to Evolving Clinical Priority

In honor of MOGAD Awareness Month, held annually in April, a new feature highlights the evolution of myelin oligodendrocyte glycoprotein antibody–associated disease from a once-misclassified condition to a distinct neuroimmunologic disorder, with commentary from Erin Longbrake, MD, PhD.

4: NeuroVoices: Yasha Kayan, MD, on Stroke, Devices, and Emerging Therapies for Neurointervention

In our latest NeuroVoices Q&A, Yasha Kayan, MD, director of neurointerventional surgery at Abbott Northwestern Hospital, part of Allina Health, discussed evolving stroke care, patient selection, and emerging neurointerventional technologies shaping clinical practice.

5: The Mechanism and Promise Behind Lu AF28996 in Advanced Parkinson Disease: Johannes Streffer, MD

In a recent interview, Johannes Streffer, MD, senior vice president of clinical development for Lundbeck, discussed the mechanism and early clinical promise of Lu AF28996, an oral dual D1/D2 agonist for advanced Parkinson disease. [WATCH TIME: 3 minutes]

Don’t have time to read or watch a full video interview? Click here to check out our short videos!